are few data on the impact of bilateral prophylactic salpingo-oophorectomy
(BSPO) on cancer mortality in BRCA1 or BRCA2 mutation carriers.
Although BPSO and bilateral prophylactic mastectomy (BPM) reduce
the incidence of breast cancer and ovarian cancer in BRCA mutation
carriers, little is known on their efficacy to reduce overall
mortality, overall cancer mortality and breast/ovarian cancer-specific
mortality. This information is now provided by a large, multicenter
and international prospective study  and is therefore critical
for clinical practice decisions about genetic counselling, mutation
testing  and choosing preventive intervention.